DAVIDavion Healthcare Plc

🇺🇸 US
1.58
USD
Analysis Scores
Lothien Robustness Score?
-
Neden bu skor?
Damodaran ?
-
Dalio Risk ?
-
Piotroski ?
4/9
Neutral
Önceki yıl borç/varlık verisi yok → kaldıraç azalması kontrol edilemedi (C5); gross profit, revenue, prev year gross profit data missing → margin comparison unavailable (C8)
Graham ?
Negatif HBK
Company is loss-making (EPS = -0.0504 TL) — Graham formula requires positive earnings
Lothien Robustness Summary
42/100
Lothien Sağlamlık: Zayıf (42/100)
Olumsuz göstergeler ağır basıyor. Finansal yapıda zayıflıklar mevcut. | Kısa Vade: Nötr | Uzun Vade: Nötr | Pozitif: 2 | Negatif: 2 | Nötr: 2
Net Zarar
Son çeyrekte -$314,957 zarar açıklandı. Yatırımcı dikkatli olmalı.
Kâr Stabil
Net kâr bir önceki çeyreğe göre fazla değişmedi (%+0.0). İstikrarlı seyir.
Yıllık Kâr Büyümesi Güçlü
Geçen yılın aynı dönemine göre net kâr %+30.5 arttı. Büyüme trendi sağlıklı.
Yüksek PD/DD
PD/DD: 29.31. Piyasa defter değerinin çok üstünde fiyatlıyor. Büyüme beklentisi primli.
Lothien Sağlamlık Skoru: 25/100
Bileşik algoritma değerlendirmesine göre şirketin finansal yapısı zayıf görünüyor.
Sonraki Çeyrek: Artış Beklentisi
Pusla tahminine göre bir sonraki çeyrekte kâr %+49.2 artabilir (-$314,957 → -$159,859).

Data date date not measured Not investment advice; the figures are rule-based model output. How the scores are computed

Score record
Data date date not measured
Update frequency Scheduled analysis run on business days at 19:30 Istanbul time; not every symbol is refreshed in every run

Method summaryThe Lothien Robustness Score (0-100) is a weighted combination of sub-scores computed by fixed rules from published financial statements and price data (Damodaran valuation, Dalio risk, Piotroski F-score, earnings quality, momentum and others). The rules are applied automatically to every covered stock, with weights that vary by sector.

AssumptionsCalculations rest on the company's latest published financial statements and on price data that may be delayed. Where four quarters have not been published, annual figures may be scaled from the available quarters. Model parameters such as the risk-free rate, the risk premium and long-term growth are fixed assumptions per exchange and contain no company-specific expectation.

Conflict of interestNo statement has been published on whether MIDAK, the operator of Lothien, or its team hold positions in these stocks. The figures are produced automatically by the same rules, without regard to any such position.

WarningThis information is not within the scope of investment advisory services and is not investment advice. The figures are the output of rule-based models and may not suit your financial situation or your risk and return preferences. Making an investment decision on the basis of this information alone may not lead to results that meet your expectations.

Model output; not investment advice; different models can disagree. Report an error

Valuation
Potential?
-
Balance Sheet Analysis? Q2026/9
Son 5 çeyrek ardışık zarar
Fiyat TRAMA-99 hafif altında: %+0.0
Direnç seviyesi: TRAMA-99 = 1.58 USD
Fundamental & Technical Analysis
Profitability
ROE - Return on Equity (TTM) %-21.2
ROE %-21.2 — negative return on equity.
Valuation
P/B Ratio 29.31x Sector: 4.55x
PD/DD 29.31x — sector median's %544 above. Expensive book value.
Indebtedness
Current Ratio 1.59x
Current ratio 1.59x — can comfortably cover short-term debts.
Debt / Equity 0.68x
Debt/Equity 0.68x — moderate financial leverage.
Interest Coverage -14.0x
Interest coverage -14.0x — critical level. Risk of difficulty in interest payments.
Growth
Net Profit Growth (YoY) %+30.5
Loss %30.5 decreased — improvement continues.
Score Explanations
Lothien Robustness
-
Weak robustness (25/100). Valuation metrics and/or debt profile are unfavorable; caution is needed.
Potential
-
Minus %36.0 expected value (1.12) vs current price comparison. 1/4 valuation models could be calculated. Model confidence %48.
Components: P/B target: 0.44
Damodaran Valuation
-
Low Damodaran score (3/100). ROIC (%-39.9) below cost of capital. DCF analysis does not support current price.
Very Weak
Dalio Risk Analysis
-
Moderate debt risk (62/100). Interest coverage ratio -14.0x — weak, fragile.
Leverage: 83/100 | Debt Service: 79/100 | Quality: 33/100
ROIC - Return on Capital
%-39.9
ROIC (%-39.9) cost of capital (15.6%) below → destroying value.
WACC: %15.6
Debt Cycle Phase
Contraction
High debt service + falling revenues. Balance sheet under pressure.
Piotroski F-Score
4/9
Neutral
Graham Intrinsic Value
—
Company is loss-making (EPS = -0.0504 TL) — Graham formula requires positive earnings
⚖️ Sector Comparison
P/B Ratio
29.31x vs 4.55x
Compared to sector %544 more expensive (by book value)
ROIC vs WACC
%-39.9 vs %15.6 WACC
ROIC 55.5 bps below cost of capital
↔
TRAMA-99 Trend — Near TRAMA
Price (1.58), TRAMA-99 line (1.58) at close levels (%+0.0). Important decision zone — breakout direction will determine the trend.
Price:: 1.58
TRAMA: 1.58
Difference: %+0.0
Charts
Indicators
BB deviation ?
RSI thresholds ?

Price Chart ?
▲ içeriden alım · ▼ içeriden satım · ★ katalizör (haber-sezgisel) · ■ 13D aktivist · ■ 13G pasif — SEC Form 4 ~2 gün gecikmeli, yalnız yönetici/direktör/%10+ sahip; katalizör = haber-sezgisel; 13D/G = %5+ pay bildirimi ~5 iş günü gecikmeli.
RSI (14) ?
Bollinger Bands ?
MACD ?

İçeriden Alım-Satım Akışı

Kim aldı, kim sattı, ne kadar

DAVI — Participation Finance Compliance
Loading…
The Lothien health scores and analyses on this page are for informational purposes only. They do not constitute investment advice. Please consult a licensed investment advisor before making investment decisions.